Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study plans to assess a new blood test for a known marker of inflammation (IL-4) in patients with heart disease.
The hypothesis of this study is that, the cytokine, IL-4, measured by a new assay, is abnormally elevated in the blood of patients with coronary artery disease.
Also hypothesized is that the degree of abnormality of blood IL-4, is related to important clinical events in such patients, including severity of disease, acute complications, and treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
"Immunoregulation in Atherosclerosis: A Single-Cell RNA Sequencing Study"
NCT06860295
Slow Coronary Artery Flow: Influence on Morbidity and Mortality
NCT00603226
Characterization of Novel Lipoprotein Properties Associated With an Increased Risk to Develop Atherosclerosis
NCT04487223
Autoantibodies and Clinical Symptoms in Infective Endocarditis Patients
NCT00562653
Platelet Leukocyte Aggregates in Acute Cardiac Syndrome vs Healthy Volunteers
NCT01797016
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The specific aims of the study are:
1. To measure IL-4 by a new rapid on-site technique in patients with documented coronary artery disease presenting in a variety of acute clinical circumstances
2. To evaluate any abnormal measurements in relation to the severity of the disease, acute vascular complication and newly prescribed medications.
It is proposed to study 4 small groups of patients with ischemic heart disease.
1. Patients with unstable coronary artery disease admitted to the Coronary Care Unit. They will be studied on admission and then daily until coronary angiography is performed.
2. Patients having coronary angioplasty. They will be studied before, immediately after and 24 hours after the procedure.
3. Patients having coronary artery bypass grafting will be studied immediately after and 24 hours post surgery.
4. Patients with stable coronary artery disease about to receive a statin and or angiotensin-converting enzyme inhibitor therapy will be studied before and twice weekly after commencement of therapy for 4 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
CROSSOVER
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Unstable coronary artery disease
Patients with unstable coronary artery disease will have daily IL6 levels
Measuring IL-4 levels
Coronary Angioplasty Patients
Patients having coronary angioplasty will have levels taken before and immediately after the proceedure and 24 hours post.
Measuring IL-4 levels
Coronary bypass grafts patients
Patients will have levels collected immediately after and 24 hours post procedure
Measuring IL-4 levels
Stable coronary Artery Diseaese Patients
Once the patients are commenced on treatment with statins and or angiotensin converting enzyme they will have twice weekly levels taken
Measuring IL-4 levels
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Measuring IL-4 levels
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Intensive Care Unit Departmental Funding
UNKNOWN
Melbourne Health
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Megan Robertson
Role: PRINCIPAL_INVESTIGATOR
Melbourne Health
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2002.156
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.